Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). In January, the FDA approved Omvoh for moderately to severely active Crohn's ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...

Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis ... The findings suggest a potential treatment target for ...

Crohn's disease and ulcerative colitis are idiopathic ... patients for whom the natural history of disease and response to treatment are predictable. The most widely held hypothesis on the ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...